| Business Summary | | Inspire
Pharmaceuticals,
Inc.
discovers
and
develops
new
drugs,
or
pharmaceutical
products,
to
treat
diseases
characterized
by
deficiencies
in
the
body's
innate
defense
mechanisms
of
mucosal
hydration
and
mucociliary
clearance,
as
well
as
other
non-mucosal
disorders.
The
Company's
products
are
based
on
its
proprietary
technology
relating
to
P2Y
receptors.
Studies
indicate
that
a
subtype
of
this
family,
the
P2Y2
receptor,
coordinates
the
mechanisms
of
mucosal
hydration
and
mucociliary
clearance.
These
complex
mechanisms,
which
involve
movement
of
salt
and
water,
a
protein
substance
made
in
specialized
cells
that
act
to
lubricate
surfaces,
called
mucin
and
the
movement
of
cilia,
or
hairlike
projections
on
the
surface
of
cells
that
move
together
in
a
sweeping
motion
to
move
liquid
and
particles
forward,
can
be
regulated
therapeutically
through
the
stimulation
of
this
receptor.
Its
lead
products
target
respiratory
and
ophthalmic
diseases
with
few
current
treatments. | More
from
Market Guide: Expanded
Business Description |
| Financial Summary | | Inspire
Pharmaceuticals,
Inc.
is
engaged
in
the
research
and
development
efforts
related
to
the
P2Y\\2\\
receptor,
which
coordinates
the
body's
innate
defense
mechanisms
of
mucosal
hydration
and
mucociliary
clearance.
For
the
six
months
ended
6/30/01,
revenues
rose
22%
to
$2.8
million.
Net
loss
applicable
to
Com.
totaled
$11.1
million,
up
from
$5.5
million.
Results
reflect
the
up-front
payment
from
Kirin
Brewery,
offset
by
increased
expense
for
drug
development
activities. | More
from
Market Guide: Significant
Developments |
| | | | FY2000
Compensation | | Pay | Exer | |
| Terrance McGuire, 45 Chairman | -- | -- | Christy Shaffer, Ph.D, 43 Pres,
CEO, Director | $273K | $503K | Gregory Mossinghoff, 40 Sr.
VP, Sec., Treasurer and CBO, Director | 235K | -- | Donald Kellerman, 46 Sr.
VP, Devel. | 221K | -- | Mary Bennett, 43 VP-Operations
and Communications | -- | -- | Dollar
amounts are as of 31-Dec-2000 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.; "Exer" is the value of options excercised during the fiscal year. |
| More
from
Market Guide on Officers & Directors: Expanded
List, Bios,
Compensation,
Options
|
|